NO20065227L - Menoklonale antistoff mot hepatocytt vekstfaktor - Google Patents

Menoklonale antistoff mot hepatocytt vekstfaktor

Info

Publication number
NO20065227L
NO20065227L NO20065227A NO20065227A NO20065227L NO 20065227 L NO20065227 L NO 20065227L NO 20065227 A NO20065227 A NO 20065227A NO 20065227 A NO20065227 A NO 20065227A NO 20065227 L NO20065227 L NO 20065227L
Authority
NO
Norway
Prior art keywords
growth factor
hepatocyte growth
antibody
menoclonal
pharmaceutical composition
Prior art date
Application number
NO20065227A
Other languages
English (en)
Norwegian (no)
Inventor
Jin Kyong Kim
Yi-Chi Su
Lihong Wang
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065227(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of NO20065227L publication Critical patent/NO20065227L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20065227A 2004-04-15 2006-11-14 Menoklonale antistoff mot hepatocytt vekstfaktor NO20065227L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor
PCT/US2004/026565 WO2005107800A1 (fr) 2004-04-15 2004-08-13 Anticorps monoclonaux du facteur de croissance des hepatocytes

Publications (1)

Publication Number Publication Date
NO20065227L true NO20065227L (no) 2007-01-10

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065227A NO20065227L (no) 2004-04-15 2006-11-14 Menoklonale antistoff mot hepatocytt vekstfaktor

Country Status (25)

Country Link
US (5) US20040208876A1 (fr)
EP (2) EP1734995B1 (fr)
JP (2) JP4594381B2 (fr)
KR (1) KR101072736B1 (fr)
CN (1) CN1964738A (fr)
AT (1) ATE473760T1 (fr)
AU (1) AU2004319276C1 (fr)
BR (1) BRPI0418745A (fr)
CA (1) CA2563080C (fr)
CR (1) CR8698A (fr)
CY (1) CY1110783T1 (fr)
DE (1) DE602004028168D1 (fr)
DK (1) DK1734995T3 (fr)
ES (1) ES2346886T3 (fr)
HR (1) HRP20100521T1 (fr)
IL (1) IL178474A (fr)
MX (1) MXPA06011822A (fr)
NO (1) NO20065227L (fr)
NZ (1) NZ550324A (fr)
PL (1) PL1734995T3 (fr)
PT (1) PT1734995E (fr)
RU (1) RU2361879C2 (fr)
SI (1) SI1734995T1 (fr)
WO (1) WO2005107800A1 (fr)
ZA (1) ZA200609407B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
KR20080026562A (ko) * 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (fr) * 2005-11-25 2007-05-31 Keio University Agent thérapeutique pour le cancer de la prostate
EP3135298B1 (fr) 2006-01-27 2018-06-06 Keio University Agents thérapeutiques pour maladie associée à la neovascularisation choroïdienne
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2025346B1 (fr) 2006-04-07 2016-08-10 Osaka University Promoteur de régénération musculaire
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
JP4560582B2 (ja) 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
AU2009246263B2 (en) * 2008-05-14 2014-08-21 Amgen Inc. Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20120052064A1 (en) * 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (fr) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anticorps anti-cMET et son utilisation pour la détection et le diagnostic du cancer
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
WO2013003680A1 (fr) 2011-06-30 2013-01-03 Genentech, Inc. Formulations d'anticorps anti-c-met
CZ2011514A3 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
US20140234328A1 (en) 2011-09-09 2014-08-21 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
EP2708556B1 (fr) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Composition pharmaceutique à utiliser dans une thérapie combinée pour la prévention ou le traitement des maladies induites par c-met ou le facteur d'angiogénèse
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
WO2015031578A1 (fr) * 2013-08-28 2015-03-05 Abbvie Inc. Dosage de hgf
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (fr) 2018-01-31 2019-08-08 元一 加藤 Agent thérapeutique pour l'asthme contenant un inhibiteur d'il-6
WO2020213665A1 (fr) 2019-04-17 2020-10-22 国立大学法人広島大学 Agent thérapeutique pour cancer urologique caractérisé en ce qu'il est administré avec un inhibiteur de il-6 et un inhibiteur de ccr2 en combinaison
WO2024229542A2 (fr) * 2023-05-05 2024-11-14 Instituto Butantan Anticorps monoclonal (mab) humain anti-fgf2, composition pharmaceutique le comprenant, utilisation de celui-ci et kit pour la détection d'un cancer dans un échantillon biologique comprenant ledit mab

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9110202D0 (en) * 1991-05-10 1991-07-03 Erba Carlo Spa Truncated forms of the hepatocyte growth factor(hgf)receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
WO2000012560A1 (fr) 1998-08-28 2000-03-09 Dendreon Corporation Apoptose selective de cellules neoplasiques mise en oeuvre par un anticorps monoclonal specifique au hla-dr
AU1598801A (en) * 1999-11-09 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The HGF-SF monoclonal antibody combinations
EP1423432A4 (fr) 2001-07-26 2006-01-11 Lilly Co Eli Anticorps vis-a-vis de l'interleukine 1 beta (il-1beta)
EP1516185A4 (fr) 2001-12-27 2007-06-20 Van Andel Res Inst Imagerie par anticorps monoclonaux et traitement de tumeurs exprimant met et se liant au facteur de croissance des hepatocytes
WO2004019991A2 (fr) 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Antagoniste nk4 du facteur de croissance de l'hepatocyte/du facteur de dispersion pour le traitement de gliome
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EP2093570A1 (fr) 2003-06-06 2009-08-26 Genentech, Inc. Modulation de l'interaction entre la chaîne HGF bêta et c-MET
CA2539190A1 (fr) 2003-07-07 2005-01-27 George F. Vande Woude Inhibition de l'angiogenese tumorale par combinaison de la thrombospondine-1 et des inhibiteurs du facteur de croissance endotheliale vasculaire
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
KR20080026562A (ko) 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
DK1734995T3 (da) 2010-10-25
HRP20100521T1 (hr) 2010-10-31
IL178474A (en) 2011-04-28
US20040208876A1 (en) 2004-10-21
BRPI0418745A (pt) 2007-12-11
PT1734995E (pt) 2010-08-18
EP1734995B1 (fr) 2010-07-14
MXPA06011822A (es) 2007-03-23
WO2005107800A1 (fr) 2005-11-17
US20070160613A1 (en) 2007-07-12
CR8698A (es) 2007-12-17
US20080019966A1 (en) 2008-01-24
CA2563080C (fr) 2015-01-27
ES2346886T3 (es) 2010-10-21
US20120064066A1 (en) 2012-03-15
US20090104192A1 (en) 2009-04-23
RU2006140257A (ru) 2008-05-20
JP2011012067A (ja) 2011-01-20
CY1110783T1 (el) 2015-06-10
ZA200609407B (en) 2008-07-30
US7494650B2 (en) 2009-02-24
RU2361879C2 (ru) 2009-07-20
IL178474A0 (en) 2007-02-11
AU2004319276A1 (en) 2005-11-17
AU2004319276B2 (en) 2010-08-26
SI1734995T1 (sl) 2010-09-30
JP2007532643A (ja) 2007-11-15
KR101072736B1 (ko) 2011-10-11
EP1734995A4 (fr) 2007-04-25
NZ550324A (en) 2009-12-24
EP2204191A1 (fr) 2010-07-07
PL1734995T3 (pl) 2010-12-31
US7687063B2 (en) 2010-03-30
DE602004028168D1 (de) 2010-08-26
JP4594381B2 (ja) 2010-12-08
ATE473760T1 (de) 2010-07-15
AU2004319276C1 (en) 2011-03-03
CN1964738A (zh) 2007-05-16
HK1094167A1 (en) 2007-03-23
CA2563080A1 (fr) 2005-11-17
KR20070012711A (ko) 2007-01-26
EP1734995A1 (fr) 2006-12-27

Similar Documents

Publication Publication Date Title
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2010054265A3 (fr) Anticorps monoclonaux anti-récepteur 2 du facteur de croissance des fibroblastes
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
HUS1500018I1 (hu) A Bruton-féle tirozin-kináz inhibitorai
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
DK1684869T3 (da) Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
CA2725873A1 (fr) Anticorps monoclonaux diriges contre un facteur de croissance fibroblastique basique
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
DK1713830T3 (da) Anti-epcam-immunglobuliner
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
ATE503527T1 (de) Selen-haltige medikamente gegen endotheliale gefässerkrankungen
UA2986U (uk) Спосіб лікування розсіяного склерозу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application